Embrace the transformative power of GLP medicationsyour comprehensive solution to slowing digestion, reducing appetite, and promoting optimal blood sugar regulation for a healthier, more balanced you
Weight reduction is an evidence-based therapy for GERD, so the weight loss achieved with GLP-1 medications may actually improve reflux symptoms in many patients, potentially offsetting any direct effects on gastric emptying
Relative gene expression was calculated after normalization to a house-keeping gene (mouse or human 18S rRNA)
For non-integrative Sendai virus mediated reprogramming, we used the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life Technologies) containing polycistronic Klf4Oct3/4Sox2, cMyc, and Klf4, according to the manufactures instructions for feeder free derivation
Why Blood Sugar May Not Be Very High In classic DKA: Insulin deficiency severe hyperglycemia In euglycemic DKA: Some insulin is still being administered Blood glucose may appear only mildly elevated But insulin is insufficient to prevent ketogenesis This can delay recognition because: Patients and clinicians may not suspect DKA with glucose under 250 mg/dL Symptoms may initially resemble dehydration or GI illness Additional Contributing Factors GLP-1 use in Type 1 diabetes may also increase DKA risk due to: Vomiting dehydration stress hormones ketone rise Intentional insulin reduction due to fear of hypoglycemia Reduced basal insulin during weight loss Increased glycemic variability from delayed gastric emptying Hypoglycemia and the Insulin Reduction Trap Another issue is the cycle that can develop: Appetite decreases Insulin dose is reduced Hypoglycemia occurs intermittently Insulin is reduced further Ketone production increases Over time, this can push the patient into metabolic instability
